Sort
51,593 grants matching “hepatitis”
Defining Natural History and Optimal Treatment Outcome for Chronic HBV Infection
$980,932Norah A. Terrault · University Of California, San Francisco · U01 · FY2014 · DK
Molecular Basis of Cancer Virus Replication, Transformation, and Innate Defense
$980,728Daniel Dimaio · Yale University · P01 · FY2016 · CA
Molecular Basis of Cancer Virus Replication, Transformation, and Innate Defense
$980,728Daniel Dimaio · Yale University · P01 · FY2017 · CA
Integration of HIV/AIDS, Viral Hepatitis, STD, and TB Programs
$980,685James W Gillan · Guam Department/ Health/Social Services · U52 · FY2015 · PS
Gulf Longitudinal Follow-up (GuLF) Study
$980,609Dale P Sandler · National Institute Of Environmental Health Sciences · ZIA · FY2014 · ES
Fibrogenesis Targeted Manganese Based MRI Contrast Agent
$980,165Vera Hoffman · Reveal Pharma · R44 · FY2023 · DK
Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection
$980,003Andrea Cuconati · Pharmabridge, Inc. · R44 · FY2012 · AI
Adult-to-Adult Living Donor Liver Transplantation Study Data Coordinating Center
$980,000Robert M Merion · University Of Michigan At Ann Arbor · U01 · FY2014 · DK
Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection
$979,945Simon Baugh · Pharmabridge, Inc. · R44 · FY2013 · AI
The role of PKD proteins in regulating tubular morphology
$979,151Gregory Germino · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK
CIP Genomics Core
$979,020Colm Ohuigin · Division Of Basic Sciences - Nci · ZIC · FY2010 · CA
Cardiovascular Disease Mechanisms in HIV Infected and Uninfected Veterans
$978,869Matthew S Freiberg · University Of Pittsburgh At Pittsburgh · R01 · FY2008 · HL
A single antiviral to treat multiple opportunistic infections
$978,771Stacy Remiszewski · Evrys Bio, Llc · R44 · FY2025 · AI
Living in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease risk
$978,740Eva Harris · University Of California Berkeley · U01 · FY2022 · AI
DRIVE (DRug use and blood-borne Infections in ViEtnam): Combined prevention and care to end the HIV epidemic among people who inject drugs in Haiphong, Viet Nam
$978,594Don C Des Jarlais · New York University · R01 · FY2019 · DA
Identification of Gene Polymorphisms Associated with Infectious Diseases
$978,326Cheryl Winkler · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Childhood Liver Disease Research Network Data Coordinating Center
$976,995John C Magee · University Of Michigan At Ann Arbor · U01 · FY2015 · DK
NDA-Enabling Phase I Lofexidine Program
$976,880James Alvan Longstreth · Us Worldmeds, Llc · U01 · FY2012 · DA
DRIVE (DRug use and blood-borne Infections in ViEtnam): Combined prevention and care to end the HIV epidemic among people who inject drugs in Haiphong, Viet Nam
$976,840Don C Des Jarlais · New York University · R01 · FY2018 · DA
A Precision Medicine for Alcohol-Associated Liver Disease
$976,742Wanqing Liu · Genetobe Inc. · UT2 · FY2023 · AA
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
$976,570Judith S. Currier · University Of California Los Angeles · UM1 · FY2025 · AI
DCTD Human Toxicology and Pharmacology
$976,485David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2017 · CA
CTN: Harvard University Northern New England Node
$976,208Roger D. Weiss · Mclean Hospital · U10 · FY2007 · DA
Intranasal Naloxone: An Opioid Overdose Antidote
$975,907Daniel Paul Wermeling · Antiop, Inc. · R42 · FY2011 · DA
Regulation of lipid metabolism by miRNAs
$975,803Alan Remaley · National Heart, Lung, And Blood Institute · ZIA · FY2010 · HL